WO2013151719A3 - Dérivés oxazolidinone fluorés - Google Patents

Dérivés oxazolidinone fluorés Download PDF

Info

Publication number
WO2013151719A3
WO2013151719A3 PCT/US2013/031405 US2013031405W WO2013151719A3 WO 2013151719 A3 WO2013151719 A3 WO 2013151719A3 US 2013031405 W US2013031405 W US 2013031405W WO 2013151719 A3 WO2013151719 A3 WO 2013151719A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluorinated
oxazolidinone derivatives
compounds
oxazolidinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/031405
Other languages
English (en)
Other versions
WO2013151719A2 (fr
Inventor
Mark E. Duggan
Takeru Furuya
D. Scott Edwards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scifluor Life Sciences Inc
Original Assignee
Scifluor Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scifluor Life Sciences Inc filed Critical Scifluor Life Sciences Inc
Publication of WO2013151719A2 publication Critical patent/WO2013151719A2/fr
Publication of WO2013151719A3 publication Critical patent/WO2013151719A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés fluorés et leur utilisation dans le domaine de la coagulation du sang. L'invention concerne plus particulièrement de nouveaux dérivés oxazolidinone fluorés du rivaroxaban et leurs sels ou solvates pharmaceutiquement acceptables ainsi que leur utilisation en tant que composés actifs du point de vue médicinal dans le traitement et la prévention de divers troubles.
PCT/US2013/031405 2012-04-05 2013-03-14 Dérivés oxazolidinone fluorés Ceased WO2013151719A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261620623P 2012-04-05 2012-04-05
US61/620,623 2012-04-05
US201261697695P 2012-09-06 2012-09-06
US61/697,695 2012-09-06

Publications (2)

Publication Number Publication Date
WO2013151719A2 WO2013151719A2 (fr) 2013-10-10
WO2013151719A3 true WO2013151719A3 (fr) 2014-03-20

Family

ID=49301151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/031405 Ceased WO2013151719A2 (fr) 2012-04-05 2013-03-14 Dérivés oxazolidinone fluorés

Country Status (1)

Country Link
WO (1) WO2013151719A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154558B2 (en) * 2016-04-15 2021-10-26 Adams Pharmaceuticals LLC Prevention of atherosclerotic events with direct factor Xa inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137274A1 (en) * 1999-12-24 2010-06-03 Bayer Schering Pharma Ag Substituted oxazolidinones and their use in the field of blood coagulation
US20100298293A1 (en) * 2007-06-20 2010-11-25 Bayer Schering Pharma Atiengesellschaft Substituted oxazolidinones and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137274A1 (en) * 1999-12-24 2010-06-03 Bayer Schering Pharma Ag Substituted oxazolidinones and their use in the field of blood coagulation
US20100298293A1 (en) * 2007-06-20 2010-11-25 Bayer Schering Pharma Atiengesellschaft Substituted oxazolidinones and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PANDEY ET AL.: "Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family", J. MED. CHEM., vol. 45, 2002, pages 3772 - 3793 *
PATANI ET AL.: "Bioisosterism: A Rational Approach in Drug Design", CHEM. REV., vol. 96, 1996, pages 3147 - 3176 *

Also Published As

Publication number Publication date
WO2013151719A2 (fr) 2013-10-10

Similar Documents

Publication Publication Date Title
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2015DN01156A (fr)
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
MY171920A (en) Prevention and treatment of ocular conditions
WO2014028591A3 (fr) Composés indazole et indole n-alkylés utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
WO2016109217A3 (fr) Inhibiteurs de la btk
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016025671A3 (fr) Traitement d'apnée du sommeil à l'aide d'une combinaison d'un inhibiteur d'anhydrase carbonique et d'un antagoniste d'aldostérone
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
WO2013151719A3 (fr) Dérivés oxazolidinone fluorés
WO2013038200A3 (fr) Troubles neurodéveloppementaux
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
NZ780408A (en) Human plasma kallikrein inhibitors
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13772272

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13772272

Country of ref document: EP

Kind code of ref document: A2